Dan Leonard Named Executive Director of We Work For Health
FOR IMMEDIATE RELEASE August 8, 2023 Washington, DC – At a time when preserving America’s leadership in life sciences innovation is...
top of page
NEWS
- Jul 7
CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on...
CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on Patients, Jobs and Cures Latest Announcement...
- Jun 14
New Study Projects Devastating Losses to Drug Develop., Jobs & Patient Health in Biopharma Ecosystem
Washington, DC – A new study estimates that there would be 237 fewer FDA approvals of new medicines for patients battling cancer,...
- Nov 21
Foot Locker, Teamsters Show Their Drug-Benefit Managers the Door
Employers and unions are getting fed up with the firms they have used for years to help control their spending on prescription...
- Nov 16
Maryland, learn from Colorado: Price controls on drugs can do more harm than good
In May 2019, Maryland became the first state to establish a board to set drug prices. But nearly five years later, the board still hasn’t...
- Nov 7
Guest commentary: Government price setting could hurt patient access and economy
For those of us working every day to grow an innovative economy in Idaho, we recognize (and at times even take for granted) the...
- Nov 2
How The IRA Could Delay Pharmaceutical Launches, Reduce Indications, And Chill Evidence Generation
Clinical development programs for new drugs include an array of research conducted both before and after a drug’s initial approval by the...
- Oct 31
We Work For Health Statement on USITC's Report on TRIPS Waiver Expansion
FOR IMMEDIATE RELEASE Nov. 1, 2023 WASHINGTON, D.C. – We Work For Health Executive Director Dan Leonard has issued the following...
- Oct 30
The Pill Penalty, Patients and Policymakers
The Centers for Medicare and Medicaid Services is continuing implementation of the Inflation Reduction Act (IRA) by holding “listening...
- Oct 23
Pharma Industry Readies for Drug Pricing Lawsuit Second Wave
Major drug companies are likely to ratchet up a sprawling legal attack aimed at challenging the Biden administration’s Medicare drug...
- Oct 10
Vital Health Podcast
Dan is the newly appointed Executive Director of We Work For Health. In this podcast, we discuss the ten drugs selected for negotiation...
- Sep 28
Voters Will Reject Inflation Reduction Act’s Assault on Medicare
In the last few weeks, House Subcommittees have conducted important hearings on President Joe Biden’s implausibly named “Inflation...
- Sep 18
Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’
Demand for new lab space has plummeted by more than half since the end of 2021, and life science vacancy rates are the highest they’ve...
- Sep 17
To Really Impact Healthcare Costs Look Beyond Drug Prices
The Inflation Reduction Act (IRA) has recently been the subject of a lot of rhetoric. While the IRA covers a number of areas...
- Sep 10
New Drug Pricing Policies Will Come at Great Expense
Regarding prescription drug costs, politicians have officially approached the “be careful what you wish for” territory. Knee-jerk ...
- Sep 10
The Inflation Reduction Act Will Lead to Fewer New Medicines
The impact of the Inflation Reduction Act on the biopharmaceutical industry is going to be substantial in a number of ways. Already...
- Sep 5
AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing law’s alleged cancer problem
Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the...
- Aug 31
Commentary: What impact the Inflation Reduction Act can have on Boston biotechs
Earlier this summer, thousands of biopharmaceutical industry leaders gathered for the BIO International Convention in the nation’s...
- Aug 29
We Work For Health Statement on Release of CMS’ Prescription Drug Negotiation List
Flawed policy approach impacts growing list of areas of unmet patient need and the American workers who support biopharmaceutical...
- Aug 28
The High Cost of Price Controls on Eliquis and Other Drugs
For years, when I visited my father in Italy, he would ask me about a drug that my company, Bristol Meyers Squibb, was developing. It was...
- Aug 28
HHS Drops First 10 Drugs for Medicare Drug Price Negotiation
The U.S. Department of Health and Human Services (HHS) on Tuesday announced the first 10 drugs covered under Medicare Part D to be...
- Aug 28
Biden administration chooses first 10 drugs for Medicare price negotiations
WASHINGTON — Medicare can now negotiate lower prices for 10 common high-price drugs, cutting out-of-pocket costs for an estimated 9...
- Aug 27
The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs
Before a once-in-a-generation pandemic struck the globe, adalimumab (Humira; AbbVie) was the most profitable drug in the world...
- Aug 27
U.S. Chamber: Biden Administration Rushes to Implement Drug Price Control Scheme...
U.S. Chamber: Biden Administration Rushes to Implement Drug Price Control Scheme, Failing to Examine the Negative Side Effects for...
- Aug 8
Dan Leonard Named Executive Director of We Work For Health
FOR IMMEDIATE RELEASE August 8, 2023 Washington, DC – At a time when preserving America’s leadership in life sciences innovation is...
- Aug 7
Opinion: This plan to cut drug prices could result in lost jobs and fewer medicines. Here’s why
Studies show the drug pricing in the Inflation Reduction Act will hurt drug research and development. Some want to take federal...
- Aug 3
Government Needs to Encourage – Not Suppress – Drug Competition
By Dan Leonard Six new copycat versions of Humira – one of the top-selling prescription drugs in the United States – just hit the...
- Jul 27
Roche: Have Abandoned Some Trials Due to U.S. Drug Pricing Plans
By Reuters FRANKFURT (Reuters) -Roche said it had abandoned certain drug development projects or acquisitions under consideration...
- Jul 26
Attempts to Expand on Prescription Drug Price Controls Put American Workers, Patients at Risk
FOR IMMEDIATE RELEASE July 26, 2023 Washington, DC – We Work for Health (WWFH) issued the following statement Wednesday in response to...
- Jul 7
CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on...
CMS Final Guidance on Government-Mandated Drug Pricing Highlights Need for Renewed Focus on Patients, Jobs and Cures Latest Announcement...
- Jul 5
Genentech CEO Alexander Hardy warns of 'unintended consequences' from the Inflation Reduction Act
It’s been almost one year since Congress and the Biden administration passed the Inflation Reduction Act (IRA), and so far leaders in the...
- Jun 27
On conference circuit, biotechs lobby for their identity as new IRA drug pricing reforms take hold
The biotech industry split off into two conference camps in early June: Oncology researchers headed to Chicago for the American Society...
- Jun 20
Biopharma Execs Weigh Controversial Move: Opting Out of Medicare to Escape Drug Price Negotiations
A panel hosted last week by JP Morgan and the industry group PhRMA further hinted at possible sweeping changes to the U.S. drug...
- Jun 15
Inflation Reduction Act is destabilizing investment in drug innovation, execs say
The science is there, but not the capital to get certain drugs to market. That means choices are being made, one says. The Inflation...
- Jun 14
New Study Projects Devastating Losses to Drug Develop., Jobs & Patient Health in Biopharma Ecosystem
Washington, DC – A new study estimates that there would be 237 fewer FDA approvals of new medicines for patients battling cancer,...
- Jun 13
IRA side effect: Pharma companies will increasingly skip Medicare altogether, Lilly CEO says
As the Centers for Medicare and Medicaid Services races to finalize guidance on how it will negotiate — or dictate, depending on if you...
- Jun 4
Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in full force here, with plenaries and poster...
- Jun 1
IRA forcing pharmas to leave cancer patients in the lurch, CEOs say
The IRA is leading pharmas to forego fast-to-patient development strategies in favor of getting onto the market first with the largest...
- May 18
Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations
Novartis has dropped some early-stage cancer drugs from its pipeline because Medicare’s new ability to negotiate certain drug prices will...
- May 8
Statement By We Work For Health on Ways & Means Hearing
Subcommittee hearing comes at a critical time on policies that negatively impact medical innovation and patient access to therapies...
- Mar 16
Amgen cites inflation, pressure on drug prices in 450-person layoff
Amgen is laying off about 450 workers, the company told Endpoints News, just two months after letting go 300 staffers...
- Mar 9
Statement By We Work For Health on Biden Administration Budget Release
Lawmakers should focus on solutions that directly support affordability, accessibility and innovation Washington, DC (March 9, 2023) – We...
- Feb 8
Statement By We Work For Health on State of the Union Address
Biden Administration should focus on fixing the IRA before its unintended consequences harm patients and workers. Washington, DC (Feb. 8,...
- Feb 7
Fix the IRA Before its Unintended Consequences Harm Patients and Workers
Read We Work For Health's letter that was sent to the Biden Administration. Washington, DC (February 7, 2023) – At We Work For Health, we...
- Jan 5
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones
FOSTER CITY, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a ...
- Nov 20, 2022
Bristol Myers Squibb warns US price reforms will dent drug development
Bristol Myers Squibb says it expects to cancel some drug development programmes due to US government drug pricing rules that are due to...
- Oct 31, 2022
Eli Lilly blames Biden's IRA for cancer drug discontinuation as the new pharma playbook takes shape
Eli Lilly laid blame Tuesday afternoon on President Joe Biden’s Inflation Reduction Act as the reason it scrapped a $40 million cancer...
- Oct 26, 2022
As Amvuttra makes inroads in ATTR, Alnylam scraps heart disease trial interim analysis
Readout for newly FDA-approved Amvuttra in a rare heart disease is on many Alnylam investors’ mind. But the company figures patience is a...
- Oct 20, 2022
Congressional User Fees Agreement Marks a Step Forward for Patients and Innovators
We Work For Health Applauds the Reauthorization of the Prescription Drug and Biosimilar User Fee Acts Washington, DC (Oct. 21, 2022) – We...
- Aug 4, 2022
A Blown Play: When Congress Treats Patients Like a Political Football, We all Lose
By Rolf Benirschke, National Co-Chair, We Work For Health As a professional football player, I never underestimated the power of a...
- Jul 31, 2022
The Far-Reaching Health, Economic & Innovation Impact of Harmful Government Price Setting Policies
By Tom Kowalski, National Co-Chair, We Work For Health This week, Congress is rushing to finalize a massive legislative proposal that...
bottom of page